With the Food and Drug Administration approving record numbers of generics, manufacturers are positioning their companies for success in the new environment.
The Association for Accessible Medicines has told members of Congress that the Hatch-Waxman Integrity Act of 2019 would decrease patient access to generics and biosimilars.